Jul 11, 2005 (financialwire.net via COMTEX) --

July 11, 2005 (FinancialWire) MIV Therapeutics, Inc. (OTCBB: MIVT) has hit scientific and business achievements in a corporate update.

The company' noted their achievements which include execution of a Letter of Intent to acquire the world's third largest manufacturer of drug-eluting stents.

The company also successfully acquired SagaX Medical Technologies, a privately held company. Both of these agreements are designed to significantly broaden MIVT's portfolio of technology and expertise. The two company's are expected to provide a major boost to its marketing and commercialization efforts.

Alan Lindsay, President and CEO of MIVT, commented, "Our concentrated efforts to develop the core strengths of our proprietary medical device coating technologies are approaching a turning point in MIVT's corporate history. Excellent results from porcine animal trials of the proprietary HAp coating technology and novel drug-eluting solutions confirm their outstanding biocompatibility and safety, and bring a promise of unique therapeutic capabilities."

Other milestones that the company reached include successful pilot preclinical studies, a Canadian grant for a research program, and exercising the option with an agreement with the University of British Columbia.

MIV Therapeutics develops of next-generation biocompatible technologies for cardiovascular disease treatments

MIV Therapeutics is covered by Investrend Research affiliate Beacon Equity Research analyst Shailesh Dhuri, who on April 6, 2005, rated the company "Outperform," with a Target of $1.53. The company was previously covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated coverage with a "Buy" rating and a $1.50 target, which was reiterated June 18, 2004. SISM Research is also distributed by the Investrend Research Syndicate. MIV Therapeutics pays SISM Research $1,750 per month

over a two-year period solely to ensure independent coverage.

Beacon Equity Research, SISM Research and Investrend Research all subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and adhere to the Guidelines for independent providers jointly endorsed by the National Investor Relations Institute (http://www.niri.org) and the CFA Institute (http://www.cfainstitute.org)

According to the New York Times (NYSE: NYT), a survey by Charles Schwab & Co. reveals an astonishing 78 percent of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating." A survey at Investopedia reveals that 74.7% of investors say that "legitimate fee-based research is objective and useful," and 70.9% say that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential."

The fee for SISM coverage was $16,500, and the fees were paid by the company to SISM. There are never any fees associated with FinancialWire, which independently covers a wide range of corporate news, including but not limited to those that are or have been enrolled in Investrend's platforms. The fee for Beacon Equity Research coverage is $18,000 for a year, and was paid by the company.

Complete information about any company enrolled in an Investrend Research affiliate platform, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

For up-to-the-minute news, features and links click on http://www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268

http://www.financialwire.net